Form 4: Haemonetics EVP Michelle Basil Reports Stock Transactions

Haemonetics Corporation EVP and General Counsel Michelle L. Basil reported the vesting of restricted stock units and associated tax withholding.

Summary

• Michelle L. Basil, EVP and General Counsel of Haemonetics Corporation, engaged in two transactions on May 15, 2026.
• 2,913 shares were withheld at a price of $56.29 per share to satisfy tax obligations related to the vesting of restricted stock units (RSUs).
• The reporting person was granted 28,424 new RSUs under the 2019 Long-Term Incentive Compensation Plan.
• Following these transactions, the reporting person holds a total of 68,829 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• The grant of 28,424 RSUs indicates continued alignment between executive compensation and long-term shareholder value.
• The reporting person maintains a significant beneficial ownership position of 68,829 shares.

Negatives

• The withholding of 2,913 shares for tax purposes represents a standard reduction in equity holdings upon vesting.

Risks

• The value of the RSU grants is subject to future market performance of Haemonetics common stock.
• Vesting of the new RSU grant is contingent upon continued employment and the terms of the 2019 Long-Term Incentive Compensation Plan.

Future Outlook

The newly granted RSUs vest in three annual installments: 40% on the first anniversary, 40% on the second, and 20% on the third anniversary of the grant date.

Management Comments

• The transactions were executed pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.

Industry Context

StockSavvy.ai notes that this filing reflects standard executive equity compensation practices within the medical technology sector, where long-term incentive plans are utilized to retain key leadership talent.

Comparison to Industry Standards

• The use of RSU vesting and tax withholding is consistent with standard corporate governance practices for executive compensation at large-cap medical device companies.
• The vesting schedule (40/40/20) is a common retention structure used by peers in the healthcare industry.

Stakeholder Impact

• Shareholders should view this as a standard executive compensation event with no immediate impact on company operations or financial position.

Next Steps

• Future vesting of the 28,424 RSUs granted on May 15, 2026, according to the three-year schedule.

Key Dates

Keywords

Haemonetics, HAE, Insider Trading, Form 4, Executive Compensation, Restricted Stock Units